vascular anomalies pipeline insight

DelveInsight’s, “Vascular Anomalies Pipeline Insight, 2026” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Vascular Anomalies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vascular Anomalies Understanding

Vascular Anomalies Overview

Vascular anomalies are a diverse group of disorders resulting from abnormal development or growth of blood vessels, lymphatic vessels, veins, arteries, or combinations of these structures. They are typically present at birth and can range from minor cosmetic lesions to severe, life-threatening conditions affecting multiple organs. According to the International Society for the Study of Vascular Anomalies (ISSVA) classification, vascular anomalies are broadly divided into vascular tumors (e.g., infantile hemangiomas) and vascular malformations (e.g., venous, lymphatic, capillary, and arteriovenous malformations). Clinical manifestations vary depending on the type, size, and location of the lesion, and management may involve observation, medical therapy, interventional procedures, or surgery.

Visible skin lesions or discoloration, including red, purple, or blue patches, swelling, or raised vascular growths that may be present at birth or develop during infancy. Pain, tenderness, or localized discomfort, particularly in venous or lymphatic malformations due to thrombosis, inflammation, or tissue compression. Progressive swelling and tissue overgrowth, which can lead to asymmetry of the face, limbs, or affected body regions. Functional impairment, such as difficulty breathing, swallowing, speaking, hearing, or vision problems when lesions involve critical anatomical structures. Bleeding, ulceration, or recurrent infections, especially in complex vascular malformations or lesions involving the skin, mucosa, or internal organ are some of the common signs and symptoms. 
Diagnosis of vascular anomalies is based on a combination of clinical evaluation, medical history, and imaging studies to determine the lesion type and extent. Ultrasound with Doppler is often the initial imaging modality used to assess vascular flow characteristics, while MRI is considered the gold standard for defining lesion anatomy and involvement of surrounding tissues. Additional investigations such as CT angiography, MR angiography, or lymphangiography may be performed for complex or high-flow lesions. In selected cases, genetic testing and histopathological examination (biopsy) can help confirm the diagnosis and identify underlying molecular abnormalities that may guide targeted treatment. Treatment of vascular anomalies depends on the lesion type, size, location, symptoms, and associated complications. Small, asymptomatic lesions may be managed with observation and regular monitoring, while symptomatic lesions often require intervention. Medical therapies include beta-blockers (e.g., Propranolol) for infantile hemangiomas and targeted agents such as Sirolimus or Alpelisib for selected vascular malformations. Minimally invasive procedures such as sclerotherapy, embolization, and laser therapy are commonly used, while surgical excision may be considered for localized or refractory lesions. 

"Vascular Anomalies Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Anomalies pipeline landscape is provided which includes the disease overview and Vascular Anomalies treatment guidelines. The assessment part of the report embraces, in depth Vascular Anomalies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Anomalies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Vascular anomalies Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Anomalies R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Anomalies.

Vascular Anomalies Emerging Drugs Analysis

This segment of the Vascular Anomalies report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular Anomalies Emerging Drugs

QTORIN 3.9% Rapamycin Anhydrous Gel: Palvella Therapeutics, Inc.

QTORIN™ 3.9% Rapamycin Anhydrous Gel is a topical small-molecule therapy containing rapamycin (sirolimus), an mTOR inhibitor. Developed by Palvella Therapeutics, it is designed to deliver localized treatment while minimizing systemic exposure. The product is being developed primarily for microcystic lymphatic malformations (mLM) and other rare vascular anomalies. By inhibiting the mTOR signaling pathway, QTORIN aims to reduce abnormal vascular and lymphatic tissue growth and improve disease-related symptoms. Currently the drug is in Phase II for Vascular Anomalies.  

Zovegalisib: Relay Therapeutics

Zovegalisib is the lead program in company’s efforts to discover and develop mutant selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers and all vascular anomalies.  Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3Kα and off-isoform activity. The Dynamo® platform enabled the discovery of zovegalisib, the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3Kα, and leveraged these insights to support the design of zovegalisib. Currently the drug is in Phase II for Vascular Anomalies.  

Further product details are provided in the report……..

Vascular Anomalies Drug Therapeutic Assessment

This segment of the report provides insights about the different Vascular Anomalies drugs segregated based on following parameters that define the scope of the report, such as:

Major Vascular anomalies Players in Vascular Anomalies

There are approx. 4+ key companies which are developing the therapies for Vascular Anomalies. The companies which have their Vascular Anomalies drug candidates in the most advanced stage, i.e. Phase III include, Palvella Therapeutics, Inc.

Vascular anomalies Clinical Trial Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Vascular anomalies Drug Route of Administration

Vascular Anomalies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Vascular anomalies Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Vascular anomalies Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular Anomalies Clinical Trial Activities 

The Vascular anomalies Pipeline report provides insights into different Vascular anomalies Clinical Trial within Phase III, II, I, preclinical and discovery stage. It also analyses Vascular Anomalies therapeutic drugs key players involved in developing key drugs. 

Vascular anomalies Pipeline Development Activities

The Vascular anomalies Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Anomalies drugs.

Vascular Anomalies Pipeline Report Insights

• Vascular Anomalies Pipeline Analysis
• Vascular anomalies Therapeutic Assessment
• Vascular anomalies Unmet Needs
• Impact of Vascular anomaliesDrugs

Vascular Anomalies Pipeline Report Assessment

• Vascular anomalies Pipeline Product Profiles
• Vascular anomalies Therapeutic Assessment
• Vascular anomalies Pipeline Assessment
• Vascular anomalies Inactive drugs assessment
• Vascular anomalies Market Unmet Needs

Key Questions Answered in the Vascular anomalies Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Vascular Anomalies drugs?
• How many Vascular Anomalies drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Anomalies?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Anomalies therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Vascular Anomalies and their status?
• What are the key designations that have been granted to the emerging drugs?

Vascular anomalies Key Players

• Palvella Therapeutics, Inc.
• Relay Therapeutics
• OnKure, Inc

Vascular anomalies Key Products

• QTORIN 3.9% Rapamycin Anhydrous Gel
• Zovegalisib
• OKI-355